Butterfly Network (BFLY) Competitors

$1.00
-0.04 (-3.85%)
(As of 05/16/2024 ET)

BFLY vs. OMER, KOD, GBIO, RIGL, OVID, IPHA, ATOS, GALT, RENB, and ADVM

Should you be buying Butterfly Network stock or one of its competitors? The main competitors of Butterfly Network include Omeros (OMER), Kodiak Sciences (KOD), Generation Bio (GBIO), Rigel Pharmaceuticals (RIGL), Ovid Therapeutics (OVID), Innate Pharma (IPHA), Atossa Therapeutics (ATOS), Galectin Therapeutics (GALT), Renovaro (RENB), and Adverum Biotechnologies (ADVM). These companies are all part of the "medical" sector.

Butterfly Network vs.

Butterfly Network (NYSE:BFLY) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Butterfly Network
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Omeros
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Omeros has lower revenue, but higher earnings than Butterfly Network. Omeros is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Butterfly Network$68.08M3.10-$133.70M-$0.58-1.72
OmerosN/AN/A-$117.81M-$1.88-1.76

Butterfly Network has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Omeros has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Omeros received 736 more outperform votes than Butterfly Network when rated by MarketBeat users. Likewise, 71.73% of users gave Omeros an outperform vote while only 62.50% of users gave Butterfly Network an outperform vote.

CompanyUnderperformOutperform
Butterfly NetworkOutperform Votes
5
62.50%
Underperform Votes
3
37.50%
OmerosOutperform Votes
741
71.73%
Underperform Votes
292
28.27%

37.8% of Butterfly Network shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 27.2% of Butterfly Network shares are owned by insiders. Comparatively, 10.9% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Omeros has a net margin of 0.00% compared to Butterfly Network's net margin of -179.09%. Butterfly Network's return on equity of -47.83% beat Omeros' return on equity.

Company Net Margins Return on Equity Return on Assets
Butterfly Network-179.09% -47.83% -35.64%
Omeros N/A -1,916.35%-35.72%

In the previous week, Omeros had 12 more articles in the media than Butterfly Network. MarketBeat recorded 14 mentions for Omeros and 2 mentions for Butterfly Network. Butterfly Network's average media sentiment score of 0.65 beat Omeros' score of 0.03 indicating that Butterfly Network is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Butterfly Network
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Omeros
1 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Butterfly Network beats Omeros on 8 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BFLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BFLY vs. The Competition

MetricButterfly NetworkX IndustryMedical SectorNYSE Exchange
Market Cap$210.71M$13.48B$5.11B$18.12B
Dividend YieldN/A1.79%37.02%3.46%
P/E Ratio-1.7231.01170.5725.60
Price / Sales3.1013.592,310.3410.81
Price / CashN/A13.0236.0019.66
Price / Book1.032.445.466.07
Net Income-$133.70M$217.86M$105.07M$966.34M
7 Day Performance3.07%0.14%1.66%1.12%
1 Month Performance11.11%7.77%3.87%6.20%
1 Year Performance-46.24%-0.45%7.88%133.97%

Butterfly Network Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OMER
Omeros
0.2369 of 5 stars
$3.64
-0.8%
N/A-37.8%$210.90MN/A-1.94198Analyst Forecast
News Coverage
Gap Down
KOD
Kodiak Sciences
3.2713 of 5 stars
$3.98
+1.0%
$5.50
+38.2%
-35.7%$209.03MN/A-0.80116News Coverage
GBIO
Generation Bio
2.0367 of 5 stars
$3.18
-5.1%
$8.00
+151.6%
-17.0%$211.44M$5.90M-1.62174Analyst Forecast
Short Interest ↑
Analyst Revision
News Coverage
Gap Down
RIGL
Rigel Pharmaceuticals
2.1373 of 5 stars
$1.19
-2.5%
$5.81
+388.4%
-23.8%$208.73M$116.88M-7.93147Analyst Revision
OVID
Ovid Therapeutics
4.372 of 5 stars
$3.00
-0.7%
$8.08
+169.4%
-6.4%$212.43M$390,000.00-4.0040Analyst Forecast
Analyst Revision
News Coverage
Positive News
IPHA
Innate Pharma
2.1877 of 5 stars
$2.63
+5.6%
$9.75
+270.7%
-10.9%$212.66M$66.71M0.00179Analyst Forecast
News Coverage
ATOS
Atossa Therapeutics
2.0081 of 5 stars
$1.70
-1.2%
$4.50
+164.7%
+125.8%$213.01MN/A-7.0812Earnings Report
Analyst Forecast
Short Interest ↓
Analyst Revision
News Coverage
GALT
Galectin Therapeutics
1.0095 of 5 stars
$3.35
-3.5%
$11.00
+228.4%
+93.8%$207.37MN/A-4.5328Earnings Report
Upcoming Earnings
Analyst Downgrade
Short Interest ↑
News Coverage
RENB
Renovaro
0 of 5 stars
$1.49
+0.7%
N/AN/A$214.07MN/A-2.1312News Coverage
Gap Up
ADVM
Adverum Biotechnologies
3.8137 of 5 stars
$10.34
-3.0%
$29.00
+180.5%
+3.1%$214.66M$3.60M-0.89121Analyst Forecast
Short Interest ↑

Related Companies and Tools

This page (NYSE:BFLY) was last updated on 5/17/2024 by MarketBeat.com Staff

From Our Partners